Immuneering Corp — Director's Dealing 2024

Feb 9, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2024-02-08

Reporting Person: Zeskind Benjamin J. (Director, PRESIDENT AND CEO, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-02-08	Stock Option	$6.09	A	244286	Acquired	2034-02-08	Class A Common Stock (244286)	Direct
2024-02-08	Stock Option	$6.70	A	16414	Acquired	2029-02-08	Class A Common Stock (16414)	Direct

Footnotes

F1: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028.